Jena in Harvard Business Review: Higher U.S. Physician Spending Doesn’t Lead to Better Outcomes
In the latest edition of the Harvard Business Review, Precision scientific advisor Anupam Jena along with co-author Yusuke Tsugawa focus on new resaerch showing that higher U.S. physician spending does not lead to better patient outcomes.
To read the complete article, please click here.
By: Jason Shafrin, PhD Sr. Director, Policy and Economics and Jacki Chou, MPL Senior Director, Policy and Economics The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize the heterogeneity in patient clinical needs and preferences.